SAVA

anygal

There are a couple of major changes: - The end of phase 2 meeting with the FDA for Alzheimer's disease went way vetter than I expected, they got greenlight for both mild and moderate Alzheimer's for low p-tau target groups. This means that the total addressable market in the US alone jumped to two and a half million people instead of roughly one hundred thousand. The FDA also told them that they can do two simultaneous 6 month Phase 3 trials if they want, which drastically reduces the time needed. This was the reason for the rally in recent weeks. - Todays news is that Breakthrough Therapy Designation for Lewy-Body Dementia got rejected. This is the reason for the crash. In my opinion there won't be any big news in the next couple of months, and for real big news we will probably have to wait a year or two now. This will be a patience game from now on, which means that the shareprice might even go lower. If you invest then you should know that this might be sideways for months, and obviously the core thesis remains the same: if the phase 3 trials succeed (either for DLB or Alzheimer's, though I am pretty sure that the management will prefer the Alzheimer's route first because of the FDA news) then this company will be worth $10+ billion in a couple of years. If they fail, then bankruptcy is definitely on the table and we will probably all lose our money. So treat this company as a high-risk high-reward lottery ticket, definitely do not put more money in than you can afford to lose (For example I lost 90% of my SAVA investment in mere minutes after they told that their trial failed)

Fragrant-Calendar-77

We'll definitely stay in this price range between $75 and $100. Just take the example of $SAVA, which went from $3 to an incredible $120. And if we see adoption of these drugs, the sky will be the limit. I calculated something a little higher, potentially reaching $300 with splits, and the market, knowing about this company (both several institutional investors and individuals), would buy CGTX shares in absurd quantities, just as they did with all the companies at the beginning of the boom when they were discovered (McDonalds, 3M, American Express, NVIDIA, Tesla, Netflix, etc.). The drugs for Alzheimer's and LDB will truly be huge, something to dream big about.

Fragrant-Calendar-77

We'll definitely stay in this price range between $75 and $100. Just take the example of $SAVA, which went from $3 to an incredible $120. And if we see adoption of these drugs, the sky will be the limit. I calculated something a little higher, potentially reaching $300 with splits, and the market, knowing about this company (both several institutional investors and individuals), would buy CGTX shares in absurd quantities, just as they did with all the companies at the beginning of the boom when they were discovered (McDonalds, 3M, American Express, NVIDIA, Tesla, Netflix, etc.). The drugs for Alzheimer's and LDB will truly be huge, something to dream big about.

ConradSchu

Shkreli was flat out telling everyone for weeks that it wouldn't work. He broke it down bit by bit, on multiple occasions, as to exactly why it wouldn't work. He fucking full ported into ATYR shorts. If you can't read both sides of a trade, and understand who has the better experience and knowledge, and explains it in detail, then you're fucked. Especially in bio-tech. This was exactly like SAVA back in November of last year. Martin warned ahead of time, and people wouldn't listen.

footballman25

FYI, $SAVA had not even close to the effectiveness as $CGTX does.

Medellin93

on and off for a year. caught SAVA and INMB

anygal

Well my main thesis definitely changed somewhat with the recent news. The Alzheimer's news was way better than I expected. I expected only mild, but they let them use their drug for both mild to moderate with low p-tau 217. Mild Alz would have been a 100-200 thousand market in the USA, mild to moderate with low p-tau is over 2 million. Also, the FDA only wants two 6 month Phase 3 trials, which significantly reduces the time needed. Still, I hoped for the DLB BTD approval by now. I reduced my position since my post, but mostly because I was crazy overextended, basically half my portfolio was in CGTX. Right now roughly 1/3 of my portfolio is in it and in the next couple of weeks I intend to reduce it to 1/5 or so, or maybe even less. That would probably still mean millions of dollars profit with a successful phase 3, but I want to mitigate my risks since we are still talking about a biotech company. (With SAVA I lost almost half my portfolio in the past. Biotech is extremely risky.)

stevenryl866

You better it’s not the next SAVA

ohgodthehorror95

Glad to see someone here who does their due diligence. The field of AZD/LBD biotech penny stocks is an absolute graveyard. INMB and SAVA being 2 well known examples. Lots of hype and failure to meet expectations. Alzheimer biotechs historically have been the riskiest and most likely to fail. I could be wrong, and someone please correct me if I am, but I'm pretty sure not a single one of these microcap biotechs has successfully passed phase 3 trials or managed to actually bring a drug to market that treats neurodegenerative diseases.

projectbaby4

Shkreli has been wrong since SAVA

anygal

No problem, its just I lost 90% once with SAVA and they also made an ATM offering before announcing their bad numbers, so I am afraid that the same might happen with ACOG. You know, fool me once, shame on you, fool me twice, shame on me :D For your sake I really-really hope that I made/am making a mistake selling and it turns out well in the long-term :D

Fragrant-Calendar-77

Don't worry about the $2.30 price you paid. In a few months, you'll be looking back wishing you had doubled the price at that price, because CGTX has enormous potential ahead of it, potentially rising much higher than $2.30. These are normal market fluctuations. Just for comparison, $SAVA, from the same Alzheimer's sector, went from $3 a few years ago to an incredible $120 (it didn't last long at that price), and it did so extremely quickly because when institutional investors discovered it, there was no way to buy it cheap. So, think about CGTX when institutional investors truly discover the potential of this drug. They will buy heavily and at whatever price it is, because they spare no effort. So, stay calm and stick to your plan to hold your shares. Our friend's post is a scroll of peace of mind and the knowledge that we CGTX investors are on the right track! It's only a matter of time! The hidden gem that is CGTX is yet to be discovered!

TrueGritty21

I’m in everything else that was incorrect and losing, does that count? Maybe I can add SAVA to my inverse portfolio

VizslaMoose

Sorry, we are in such different worlds on almost everything you said. I don’t invest in a company to dabble. I do my diligence and then I make a significant investment. I don’t invest in biotech stocks to mitigate losses. Risk management is what my index funds are for. I certainly don’t do that in extremely binary companies like this - where the stock goes crazy or goes to zero. My question is a due diligence question. What makes this company so much more compelling than a BIVI or SAVA or ANVS or a whole list of others that have failed despite tantalizing data in early-to-mid stage companies? And as I look more carefully at the data now, what makes us think the effect will be durable? The DLB actually looks very good - but is it durable? However, as I do my due diligence, honestly just on the DLB data this company is wildly under-valued. It’s a shame they are pushing Alzheimer’s ahead of that, where the data is less convincing.

OppositeArt8562

FDA just gave CGTX a sweetheart 6 month phase three. While the actual trial itself is usually several years long, the **FDA review of a New Drug Application (NDA) or Biologics License Application (BLA) can be expedited to 6 months in cases of Priority Review.** This happens for drugs that demonstrate a potential for significant improvement in treating, diagnosing, or preventing serious conditions. Approximately 25% of new molecular entities receive Priority Review designation. This could be the real thing. They wouldn't do this after SAVA and other recent "almosts" without some level of confidence.

anygal

I was also really deep in SAVA, lost a significant part of my portfolio. I put way more in it than I should have. Well, live and learn. I think that CGTX-es recent results are amazing, but with biotech you never know. Don't be like me, put only as much into it as you can afford to lose :)

Entire_Strike_2786

Yep lol. I lost a lot in SAVA but I intend to add a small position here. Market cap is still very small which is the main reason for me.

Aware-Celebration873

You admit he was right with SAVA so why wouldn't he be right with this if he decided to short it. They are making a drug that supposal cures a disease like alzheimer's something that is vastly complex , no one in the world knows where it comes from and how it works apart from it develops plaque in the brain.

retardedape2

I heard this one once before... RIP in peace SAVA.

anygal

SAVA were valued way over $2 billion after they announced their phase 3 greenlight and they shot up as much as $5 billion dollars even though their phase 2 results were nowhere as good as the CGTX results (40-50% slowing of cognitive decline vs 95% for CGTX-es low p-tau target group [roughly 30% of overall Alzheimer'spopulation]). Obviously later they failed phase 3 but they were trading at 20x-25x of CGTX-es current market cap for years after their phase 2. Just three months ago Sanofi acquired Vigil Neuroscience for $470 million after their phase one (not even phase two). AVXL currently trades at $900 million dollars, even though their drug has a less than 50% cognition decline reduction and they didn't even go for FDA approval for over a year now, they only shoot for Europe

Primary-Donkey100

I got PTSD of SAVA so even though this stock seems interesting, I will most likely stay out🤣

Fragrant-Calendar-77

The price is the sky is the limit.. $SAVA, which is also an Alzheimer's biotechnology, years ago went from $3 to an incredible $120 (it didn't hold for long), but to give you an idea of the real potential of CGTX

anygal

Why would it be over? SAVA was valued over $2 billion after they got their phase 3 greenlight and they had nowhere near as great phase 2 as CGTX. CGTX is still valued at like $100 million or so, so there could be an over 2000% upside even from there (and who knows what is the ceiling if their phase 3 succeeds)

Heavenly-alligator

I once traded on the opposite end of him in $SAVA and I got burnt real well that made me think that dude knows a thing or 2 about bio stocks Having said that the guy is an asshole

bigzork

If I'm not mistaken SAVA's odds were estimated to be less than 20% chance of success while ATYR seems to be at least double that

Entire-Philosophy-86

I dont get this comparison. SAVA was not looking good at all lmao.

OortBelt

Everyone keep talking about SAVA when they want to sound bearish about a biotech. Change disk, would you ?

Emergency-Eye-2165

I was balled deep in SAVA back in the day, then did some DD and got the fuck out! Sometimes you just get caught up in the moment then realize, wait… this is a pump and dump!

ohgodthehorror95

He was dead on the money with SAVA and INMB though.

Parking-Rabbit-4371

Bought SAVA at 12$ it went to 144$ made 140k, kept buying speculative stocks until I lost it all in the 2022 dump

Adventurous-Rub-6980

No problem — I get what you mean. Alzheimer’s is a tough space long-term, no doubt. But take Cassava ($SAVA) — it went from under $2 to over $100 in less than a year just off early data and hype. Sure, it’s back down now, but it shows what kind of run is possible in the mid-term when momentum and catalysts line up.

Immediate_Tale_5657

Healthcare market is going up fast. I highly recommend these dollar stocks: SAVA and OCGN

Fox2_Fox2

> It’s either going to be big or a complete bust. Very tempting to average up but my experience with SAVA keeps telling me not to 😂

oh19567

$SAVA is being shorted heavily. There are a few big institutional buyers. We should look into them.

SockApprehensive7837

Sorry to whoever had this stock. It reminded me of SAVA's crash some months ago when I was lucky to sell a week before the stock plummeted.

Fox2_Fox2

I remember he crapped on SAVA and he was right.

RRRRRRRRREEEEEEEEEE

Worst was SAVA, lost 90%. Best are ASTS, PLTR, and SMR, all up over 400%. Hopefully I can add QS and SLDP to the list soon.

anygal

Two catches. 1. In my opinion they will need further dilution, even after the $80+ million grant. 2. This is a biotech company. There is always a chance that their trials succeeded by sheer luck and phase 3 fails miserably (see SAVA for example). So DO NOT put your life-savings into this play, see it as a lottery ticket with higher chances to win. The data is really promising but really anything can happen in the biotech space.

cautiouslyPessimisx

Keep your head up and learn from your mistakes. I had a big, $272K loss on $SAVA (or $700K if you look at the portfolio's peak value). I learned and am moving on... just more carefully this time...

EventHorizonbyGA

That has happened with $TARA and a numerous other biotechs. None of them have changed their names. I run a family office and a biotech centered fund. My interest here is simply because these single thesis heavy biotechs $SAVA, $INMB, $ATYR, etc are heavily manipulated by funds and insiders through social media feedback loops.

MetalExpensive4530

Delusional fuck will regret like that doctor who invested like $20 mil in $SAVA

anygal

Story of my life. When I buy something it usually crashes in a day or two :D The good news is that long-term my picks tend to go up and become profitable, though mistakes do happen. I lost 90% of my cost basis with SAVA for example. If you are interested in my opinion (you shouldn't be, I am usually dead wrong for short-term) I think that the shareprice will probably go down until the end-of-phase 2 official minutes come out (2-4 weeks from now), then either crash or shoot up again. If its bad news then I'll trim my position somewhat, but I'll wait out if the FDA approves their breakthrough Lewy Body Dementia therapy (3-7 weeks from now). If it is not approved then I'll take my losses and cash out, if it is approved then I remain and wait for my 500x :D

icantbeassedman

Martin Shkreli is short on CAPR, that is all you need to know. Matt Nachtrab lost 70 million with SAVA while Shkreli made a million shorting SAVA

Will_Knot_Respond

Oh snap SAVA hooked another newbie lol gl pal!

killerdrgn

So you're saying this time researchers can't also falsify data. Cause SAVA was saying they didn't falsify data, until it was exposed that they did.

killerdrgn

This seems like all the same arguments and price action for SAVA.

Robinw9787

He got credibility for much more than SAVA lol

baroo88

You must have missed the part about him being down almost 100% since he shorted. So much credibility given for shorting SAVA while they were already under investigation for fraud. 

ohgodthehorror95

The short interest is so high, that it could squeeze regardless if redditors from WSB, r/shortsqueeze, etc pile in and buy. Or it ends up falling to nothing. SAVA got away with some schetchy stuff even as the house of cards was collapsing.

Bouddha_420

SAVA announced on a Sunday a webcast the following day at 8am to present P3 topline data, giving no time to market participants (understandably) INMB PRs yesterday for a webcast on Monday (4 days later), making sure this gives sufficient time for anyone who has not yet done their DD to get up to speed, and also giving the opportunity to get as much news coverage ahead of the webcast and get all the spotlight... I really wonder why 🤔

anygal

Oh you don't have to tell me about SAVA, I got out at a 90% loss. One of my biggest losses since I have started investing (probably the second biggest by money amount). Actually with CGTX I am mich more interested in their Lewy Body Dementia drug, the phase 2 results were spectacular! Their Alzheimer's trial is just a bonus.

ProblemOk4641

How many have tried and how many have failed to cure Alzheimer’s! Be v careful. Pls take a look at $SAVA. That was always the big hope but completely tanked when the fda rejected.

kennetec

For a minute there I thought the ticker he was spamming was SAVA and I had flashbacks.

kwijibokwijibo

SAVA Got out not long before it went -95% lol

WitchKitty777

Your comment makes no sense. AVXL already released positive results and a peer reviewed article backed by 58 AD specialists. How does this compare to SAVA which failed completely? Did you do any research before making this comment?

anygal

Hi OP, I was in your shoes. I have made $3 million from roughly $40k in a single year even though I always said it was 98% luck (unlike you). You have to understand a couple of extremely important things: - First of all, never give financial advice to others, UNLESS they specifically ask for them and even then tell them to also do their own due diligence on the company you suggest and do not forget that you are a human. - Second, and even more important, never ever blame others for your mistakes. Oh, your brother/friend/father/advisor said that there is a great company and you invested in it $1-200k? It is all on you. Own it. Maybe your due diligence was not deep enough or you checked out the wrong boxes. It was still you who bought in. - Third, and maybe most important of all: if you are taking the route of individual investing then mistakes will happen. Last year I was so highly convicted in a company (SAVA) that I put half of my portfolio in it. It dropped 90% in a single day, because their phase 3 trial failed. Shit happens dude, what you can do is learn from it. - Fourth: there is ALWAYS luck involved, whether you want it or not. Maybe you are investing into a microcap with a star CEO genius and the next day he/she gets ran over by a train. Dramatic example, but these types of shit can happen. So yeah. Do decent due diligence and if you have found a company that you think will grow a lot in value/extremely undervalued even now, then go for it. Do not put in 100k, put in 2-5% of your portfolio. Find 10 companies like that and let the rest of your (50-80%) money sit in bonds/S&P500/All-World/anything less risky compared to individual investing. You can do this dude, you already do better financially than most people!

anygal

Well there is also a risk that an affordable disease-modifying wonderdrug comes out, but after the SAVA failure I think that it is definitely at least a couple of years away. In my opinion at this point the biggest risk is that some serious side-effect emerges and affects a lot of Zunveyl patients, so the distribution of the drug gets halted. I have a lot of eggs in this basket, so hopefully this won't happen, but it important to know that it could.

anygal

This company is already approved, launched Zunveyl and selling it since late March. (I have lost a lot of money on SAVA though, thankfully not ALL of my eggs were in one basket)

anygal

I feel you, just a couple of months ago I have lost basically half my portfolio's worth on SAVA :D

peopeopeopeo10

Is WOLF like a UNH scenario or more like a SAVA?

backwardsfrog

SAVA plummeted because it failed to pass phase 3 trials. IOVA's Amtagvi is already FDA approved and has treated hundreds of patients. Main problem right now is in the roll-out, which is significantly less risky.

killerdrgn

Lol this is definitely the next SAVA.

Scared_Inside6556

I bought SAVA at $1 32 and sold out at $50. Then it shot up to over $100 in 2021 and crashed back down to $2. First I felt bad for selling too early, but now I feel like I dodged a bullet. Now I'm riding with WOLF and trying to figure out the best exit strategy when it hits double digits.

HontonoKershpleiter

Watching SAVA and PLRX today, they look ready to move

Ratchet_as_fuck

I've been too busy to research stocks so my investments have been broader. Currently bullish on Bitcoin and certain crypto related stocks like COIN. But don't have any special someone's like SAVA.

Qcuzmih

Man, good for you. You may have found a niche that eventually could be very profitable. CC's are generally the safer type of options but they do tie up cash quite a bit. Those 2 stocks have a bit of scary 1yr track record (e.g. SAVA in Nov'24) which I don't have the stomach for. Hope it keeps doing well for you going forward.

Open-Attention-8286

I have no illusions about this being sustainable. Like I said, I'm working on improving my situation. I'm applying for jobs, looking for freelance/gig opportunities, taking free coding lessons online, hell I even checked into the idea of being a paid plasma donor (didn't qualify). Everything I can think of that is in my power to do, I'm trying it. The real list of things I'm trying is too long to be worth typing out. But until something else works, this is what I've got. And it's bringing in *just* enough so far. I may be hanging on by my fingernails, but I'm hanging on. As for what I'm investing in, I have 2 screeners set up to identify covered-call opportunities with the highest yields. I'm looking for underlying equities that are $30 or less, with one screener checking options that are 8 days or less til expiration, and the other at 5 weeks or less. For example, as of 5 seconds before typing this, AREC was selling at $1.33 per share. The $1.5 May 16 call option was going for 0.35/0.40. If I had sold it at $0.35, that would be a return of around 26%. Then, whenever possible I would take whatever I made from that and put it towards something that expires sooner. Just at a glance, looks like SAVA has one that expires next week that would give me a 5% return. That's just an example. Right now I'm waiting on some that expire tomorrow to free up some cash.

SIR_NVAX_A_LOT

Biotech plays are ultra risky. See exhibit A $SAVA Cassava Science.

ProblemOk4641

Everybody has a sob story about bios. Relying on fda to approve or not approve is a big gamble. Non approval or a delay tanks the stock like we saw. I warned a few people on the chat. I always revert back to $SAVA, many people lost all of their savings!

OnundTreefoot

Simufilam was a scam from the start. The selective release of cherry-picked OL data was criminal and I hope Burns and Barbier see some prison time. SAVA people lost a lot of money. I tried to warn retail stock holders on several boards but they simply called me a short. Nice people but emotionally attached to the wrong idea.

PKoderDE

Bothe these stocks fkd me up. One bought at 14$ NMRA and SAVA at 4$

mycatlikesluffas

My SAVA pills made me forget 

xampf2

If analysts could predict the stock market, everyone would just follow their advice and make bank. This is clearly not the case. To understand why, you should look into who pays these sell-side analysts to produce predictions and what kind of other incentives there are. For example, analysts don't like to be contrarian it's safer to follow the herd. You won't get fired for setting $TSLA target price to $400 like everyone else but saying it goes to $10 and it won't will just get you fired. Also since you are just starting out. Do not invest into biotech unless you know biotechnology, pharamacology, clinic trials, statistics etc. Most biotech startups go to $0 and there is maybe one in a dozen that does a 20x. If you have no clue about how to detect fraud and nonsense you will get shafted. And no, most redditors won't be able to tell you and be very convincing about their favorite biotech stock. Just study the history of $SAVA (check my comment history) to understand what is going on. It's probably smarter to short biotech stocks rathern than going long.

NoleScole

Sell right now and put it in cash. Then when the market is going up, and at it's all time high buy calls on SNAP, RIOT and SAVA. Then to "hedge" against the risks I'll buy ETFs since they're "up now." Then sell them again when the market goes down. The calls will expire out of money. Rinse and repeat.

Nebula_Whinch

You could have lost it all on SAVA that would be worse… although SAVA still has a little hope left…

One_Definition4812

https://preview.redd.it/nf4fgoxrw2le1.png?width=884&format=png&auto=webp&s=cb946a620752b8c3069f31fa4eba2782e7c859db I took an easy Delta (DAL) trade this morning. I plan to buy some SAVA Sciences (SAVA) $7.5 June Calls and Disney (DIS) $105 April Puts. I'm also considering Bitfarm (BITF) January 2026 $2 Calls.

genjky

Puts on SAVA. it's had a weird runup recently for no reason.

EuphoricAd3824

SAVA. Lost about 85%, There were signs that they would fail but was so emotionally invested that they would be able to solve the alzheimer problem that I stayed invested.

Rocket-Man-LetsGo

I know SAVA is in hot water, but it has had a couple historical king making pumps over the years. Any possibility left for this one?

RevolutionaryPhoto24

Freaking SAVA…

Inner-Alps9101

SAVA

nicefoodnstuff

Nio and SAVA

anygal

I have no idea about short-term, but I was always an abysmal short-term trader. This is why now I only invest on fundamentals and for long-term. I honestly think that this should go up a lot (way over the recent $20 premarket high) on the 100% QoQ and YoY revenue growth for Q4, but there could be something that I don't see. Just a couple of months ago I was 99% sure that the SAVA phase 3 trials will succeed, then it failed and I lost like 80+% on that, so sadly I am not always right, even if I think otherwise. Still, I am in and remain in until either fundamentals prove me right or wrong.

curious_skeptic

It doesn't help when you're being run by untrustworthy folks. SAVA was for suckers (and still is!)

FromZeroToLegend

I saw some regard on r/thetagang bragging about his short calls on RGTI. Reminds me of the regard who blew up his port selling SAVA puts before they went down 90%. Truly we’re living in the most regarded of times

FromZeroToLegend

I have. That’s how I made about $70K shorting SAVA.

jusjones314

Maybe I'm stupid and don't understand how short covering works, but maybe I'm not also and SAVA is going to explode up when it hits 2.00 and shorts get closed out. Not back to 30, but maybe to 4.50 or so?

whoisbatman

Didn’t you follow SAVA? I’ll not touch any small Pharma/Biotech companies … it’s literally ticking bomb in the making…

absvdvdb

$SAVA

ghostofwinter88

High premium on high IV isnt free money. You're being paid for higher risk. Do you have any experience investing in biotech? Neumora is a loss-making preclinical startup with several therapies for neurological disease in the works. They have several Trial results imminent; one is supposed to release before the end of the year, a few others in q1. The IV is high because people are expecting big swings in the price. If their trials succeeds, great, it will moon. If not, shares tank. They have enough funding until mid 2026, but if this fails they wont havr much time left to do a second trial. This is make or break for the company. This is exactly ehat happebed to SAVA just a few weeks ago. I dont have the technical expertise to judge their therapies chance of success but neurological diseases are notoriously difficult to treat. You are betting on the success of their clinical trials. Once those trial results come out, IV is likely to drop quite hard (IV crush) and hence premiums will also drop. Theres no guarantee you can sell those calls for a good price, or if there will be appreciable volume if those trials fail.

Enough-Mud3116

I have no confidence puts will print before expiration. SAVA shenanigans went for FOUR years before crashing.

St0nkLady

Thank you, fair point, I don't ever think of TSLA having a SAVA moment... but it could one day. I'll look into QYLD.

StrikingMonkey

Right on SAVA. Wrong on HUMA, BTC, DJT and Quantum Computing. Right on GALT, though.

Jdesey9999

what am I missing here.. SAVA puts for 20 strike only went up 100%... with a 90% drop on SAVA I would have expected more.. now on GALT.. it is only a $2 stock,,, I mean what is the best we could hope for.. it goes to under $1.. and then what profit do the puts make?

Jdesey9999

yeah this is pharma bro..... what I cannot believe is that SAVA dropped by 90% and the puts only went up 100%... that easily should be a 10X

clavidk

Yeah his $SAVA short thesis had a 14:1 risk reward while this one is only 1.6:1...

Jdesey9999

Who made that prediction on SAVA cause holy man they got it right. Maybe I’ll just take a put here and see what happens. I’m sick of daytrading

onamixt

Nah, this is nothing like SAVA. DoD needs the technology.

AZXHR1

I don’t speculate a lot and haven’t for the past 1-2 months due to exams. But these past 6 months have been: Broadcom (AVGO) - @ 148$ & 160$. Taiwan Semi (TSM): - @ 175$. NVDA: - @ 105$, 119$, 139$, 115$, 127$ (yesterday). LUNR: - @ 7.9$, sold most now. MSFT: - @ 405$ & 425$. Short SAVA: - @ 25$ in Oct. VOO: - @ 476$ (lucky timing) BRK.B bought at the same time as VOO, only up something like 2-5%. I’m stupidly tech heavy, but it have paid back a ton the past few months. Haven’t gambled on options yet, not planning to either, but i will DEFINITLY use it to dynamically hedge my positions in the future since i finally fixed an appropriate broker to use. Going to learn about heavy options (black-scholes model, etc) & futures this semester, already started on the subjects so i’m ahead for the beginning of the year. Did use IBKR & another one, but have since changed. No plan as of now to buy, but i’ll see, gotta transfer some funds and positions first. Plus the fed meeting is today, which will definitly affect the market depending on the outcome.

underappreciatedduck

Don't do it. GALT is due to announce results, the stock will be worthless afterwards. GALT is SAVA level trash. The December puts are purely speculative because they said they will announce in December and this week is theoretically the only "non-troll" week to release any data. However it could be that it slips into January which is after Shareholder meeting...there is no way they will delay past that. Long story short: Don't be bullish on GALT. You will lose on those Puts.